Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1475 of 1812 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/15/17
End: 08/30/18
Due: 08/30/19
Phase: N/A
Priority: Normal
Start: 03/31/16
End: 06/12/19
Due: 06/12/20
Phase: N/A
Priority: Normal
Start: 07/31/10
End: 07/31/15
Due: 07/31/16
Phase: N/A
Priority: Normal
Start: 04/30/16
End: 07/31/18
Due: 07/31/19
Phase: N/A
Priority: Normal
Start: 10/31/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/10
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/27/23
End: 12/01/26
Due: 12/01/27
Phase: N/A
Priority: Normal
Start: 01/31/13
End: 04/30/13
Due: 04/30/14
Phase: N/A
Priority: Normal
Start: 11/30/11
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/15
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 03/31/08
End: 04/30/09
Due: 04/30/10
Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
Phase: N/A
Priority: Normal
Start: 06/08/18
End: 04/30/21
Due: 04/30/22
Phase: N/A
Priority: Normal
Start: 04/30/16
End: 01/07/19
Due: 01/07/20
Phase: N/A
Priority: Normal
Start: 09/30/15
End: 02/28/18
Due: 02/28/19
Phase: N/A
Priority: Normal
Start: 02/01/25
End: 12/31/29
Due: 12/31/30
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 11/30/16
Due: 11/30/17
Phase: N/A
Priority: Normal
Start: 08/30/21
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 03/31/13
Due: 03/31/14
Phase: N/A
Priority: Normal
Start: 04/01/24
End: 04/15/25
Due: 04/15/26
Phase: N/A
Priority: Normal
Start: 12/31/05
End: 02/29/08
Due: 02/28/09
Phase: N/A
Priority: Normal
Start: 03/11/19
End: 12/09/19
Due: 12/09/20
Phase: N/A
Priority: Normal
Start: 08/01/21
End: 04/30/22
Due: 04/30/23
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 04/28/17
Due: 04/28/18
Phase: N/A
Priority: Normal
Start: 03/31/11
End: 10/31/11
Due: 10/31/12
Phase: N/A
Priority: Normal
Start: 09/30/08
End: 03/31/10
Due: 03/31/11